诺华(NVS.US)的镥 [177Lu] 特昔维匹肽上市申请获 CDE 受理

智通财经11-13

智通财经APP获悉，11 月 13 日，诺华(NVS.US)的镥 [177Lu] 特昔维匹肽上市申请获 CDE 受理。此前该药已被 CDE 纳入优先审评，适用于治疗前列腺特异性膜抗原（PSMA）阳性转移性去势抵抗性前列腺癌（mCRPC) 、已接受雄激素受体通路抑制和紫杉类化疗的成年患者。该药是 FDA 批准的首个针对去势抵抗性前列腺癌患者的靶向放射性配体疗法，本次是在国内首次报上市。

以放射配体疗法为代表的核药是诺华重金布局的领域。除了 Pluvicto，诺华还有一款核药 Lutathera 也已获批上市，用于生长抑素受体阳性（SSTR+）胃肠胰神经内分泌肿瘤成人患者，后又获批用于12 岁及以上儿童患者。Lutathera 2023 年销售额达 6.05 亿美元，2024 前三个季度销售额为 5.34 亿美元。

截图来源：CDE 官网

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2483151011?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-13 10:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483151011","market":"sh","top_or_hot":-1,"title":"诺华(NVS.US)的镥 [177Lu] 特昔维匹肽上市申请获 CDE 受理","media":"智通财经","content":"<html><body><p>智通财经APP获悉，11 月 13 日，<a href=\"https://laohu8.com/S/NVS\">诺华</a>(NVS.US)的<strong>镥 [177Lu] 特昔维匹肽</strong>上市申请获 CDE 受理。此前该药已被 CDE 纳入优先审评，适用于治疗<strong>前列腺特异性膜抗原（PSMA）阳性转移性去势抵抗性前列腺癌（mCRPC) </strong>、已接受雄激素受体通路抑制和紫杉类化疗的成年患者。<strong>该药是 FDA 批准的首个针对</strong>去势抵抗性前列腺癌<strong>患者的靶向放射性配体疗法，本次是在国内首次报上市</strong>。</p><p><strong>以放射配体疗法为代表的核药是诺华重金布局的领域</strong><span>。除了 Pluvicto，诺华还有一款核药 Lutathera 也已获批上市，用于生长抑素受体阳性（SSTR+）胃肠胰神经内分泌肿瘤成人患者， 后又获批用于12 岁及以上儿童患者。</span><strong>Lutathera 2023 年销售额达 6.05 亿美元，2024 前三个季度销售额为 5.34 亿美元</strong><span>。</span></p><p><img src=\"http://img.zhitongcaijing.com/images/contentformat/dd56ca04461c739648e59b38423346c4.jpg\"/></p><p>截图来源：CDE 官网</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺华(NVS.US)的镥 [177Lu] 特昔维匹肽上市申请获 CDE 受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺华(NVS.US)的镥 [177Lu] 特昔维匹肽上市申请获 CDE 受理\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2024-11-13 10:54</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP获悉，11 月 13 日，<a href=\"https://laohu8.com/S/NVS\">诺华</a>(NVS.US)的<strong>镥 [177Lu] 特昔维匹肽</strong>上市申请获 CDE 受理。此前该药已被 CDE 纳入优先审评，适用于治疗<strong>前列腺特异性膜抗原（PSMA）阳性转移性去势抵抗性前列腺癌（mCRPC) </strong>、已接受雄激素受体通路抑制和紫杉类化疗的成年患者。<strong>该药是 FDA 批准的首个针对</strong>去势抵抗性前列腺癌<strong>患者的靶向放射性配体疗法，本次是在国内首次报上市</strong>。</p><p><strong>以放射配体疗法为代表的核药是诺华重金布局的领域</strong><span>。除了 Pluvicto，诺华还有一款核药 Lutathera 也已获批上市，用于生长抑素受体阳性（SSTR+）胃肠胰神经内分泌肿瘤成人患者， 后又获批用于12 岁及以上儿童患者。</span><strong>Lutathera 2023 年销售额达 6.05 亿美元，2024 前三个季度销售额为 5.34 亿美元</strong><span>。</span></p><p><img src=\"http://img.zhitongcaijing.com/images/contentformat/dd56ca04461c739648e59b38423346c4.jpg\"/></p><p>截图来源：CDE 官网</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1210232.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1210232.html","article_id":"2483151011","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483151011","pubTimestamp":1731466452,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，11 月 13 日，诺华的镥 [177Lu] 特昔维匹肽上市申请获 CDE 受理。该药是 FDA 批准的首个针对去势抵抗性前列腺癌患者的靶向放射性配体疗法，本次是在国内首次报上市。以放射配体疗法为代表的核药是诺华重金布局的领域。除了 Pluvicto，诺华还有一款核药 Lutathera 也已获批上市，用于生长抑素受体阳性胃肠胰神经内分泌肿瘤成人患者， 后又获批用于12 岁及以上儿童患者。Lutathera 2023 年销售额达 6.05 亿美元，2024 前三个季度销售额为 5.34 亿美元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4588":"碎股","CDE":"科尔黛伦矿业","NVS":"诺华","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4007":"制药","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4532":"文艺复兴科技持仓","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4017":"黄金","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4578":"CAR-T","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4585":"ETF&股票定投概念","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC"},"translate_title":"Novartis (NVS.US) 's lutetium [177Lu] texivipitide marketing application was accepted by CDE","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDE":1,"NVS":1},"content_text":"智通财经APP获悉，11 月 13 日，诺华(NVS.US)的镥 [177Lu] 特昔维匹肽上市申请获 CDE 受理。此前该药已被 CDE 纳入优先审评，适用于治疗前列腺特异性膜抗原（PSMA）阳性转移性去势抵抗性前列腺癌（mCRPC) 、已接受雄激素受体通路抑制和紫杉类化疗的成年患者。该药是 FDA 批准的首个针对去势抵抗性前列腺癌患者的靶向放射性配体疗法，本次是在国内首次报上市。以放射配体疗法为代表的核药是诺华重金布局的领域。除了 Pluvicto，诺华还有一款核药 Lutathera 也已获批上市，用于生长抑素受体阳性（SSTR+）胃肠胰神经内分泌肿瘤成人患者， 后又获批用于12 岁及以上儿童患者。Lutathera 2023 年销售额达 6.05 亿美元，2024 前三个季度销售额为 5.34 亿美元。截图来源：CDE 官网","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483151011"}